Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
CNBC Markets · Thu, 29 Oct 2026 11:44:57 GMT
Read the full story at CNBC Markets ↗OmniFin Portal's take
Excerpt from CNBC Markets: “Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.”
Rule-based headline sentiment: Bullish
More Stocks headlines
President of the European Central Bank Christine Lagarde to step down. Here's who is tipped to replace her— CNBC MarketsCaterpillar’s stock heads for worst day in 7 years — and what that means for the Dow— MarketWatchDoorDash to acquire Instacart for $17 billion— CNBC MarketsAI build-out hits snag as Google and Microsoft put off raising capex forecasts— CNBC Markets